<article xmlns="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle http://dtd.nlm.nih.gov/2.0/xsd/archivearticle.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Anal Biochem</journal-id>
      <journal-title>Analytical Biochemistry</journal-title>
      <issn pub-type="ppub">0003-2697</issn>
      <issn pub-type="epub">1096-0309</issn>
      <publisher>
        <publisher-name>Academic Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">2789237</article-id>
      <article-id pub-id-type="pmid">19748480</article-id>
      <article-id pub-id-type="publisher-id">YABIO9614</article-id>
      <article-id pub-id-type="doi">10.1016/j.ab.2009.09.003</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Development and validation of a cytochrome <italic>c</italic>-coupled assay for pteridine reductase 1 and dihydrofolate reductase</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Shanks</surname>
            <given-names>Emma J.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ong</surname>
            <given-names>Han B.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Robinson</surname>
            <given-names>David A.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thompson</surname>
            <given-names>Stephen</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sienkiewicz</surname>
            <given-names>Natasha</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fairlamb</surname>
            <given-names>Alan H.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Frearson</surname>
            <given-names>Julie A.</given-names>
          </name>
          <email>j.a.frearson@dundee.ac.uk</email>
          <xref rid="cor1" ref-type="corresp">⁎</xref>
        </contrib>
      </contrib-group>
      <aff>
        <addr-line>Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, UK</addr-line>
      </aff>
      <author-notes>
        <corresp id="cor1"><label>⁎</label>Corresponding author. Fax: +44 1382 385764. <email>j.a.frearson@dundee.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>15</day>
        <month>1</month>
        <year>2010</year>
      </pub-date>
      <volume>396</volume>
      <issue>2</issue>
      <fpage>194</fpage>
      <lpage>203</lpage>
      <history>
        <date date-type="received">
          <day>8</day>
          <month>6</month>
          <year>2009</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2010 Elsevier Inc.</copyright-statement>
        <copyright-year>2009</copyright-year>
        <copyright-holder>Elsevier Inc.</copyright-holder>
        <license>
          <p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</p>
        </license>
      </permissions>
      <abstract>
        <title>Abstract</title>
        <p>Activity of the pterin- and folate-salvaging enzymes pteridine reductase 1 (PTR1) and dihydrofolate reductase–thymidylate synthetase (DHFR-TS) is commonly measured as a decrease in absorbance at 340 nm, corresponding to oxidation of nicotinamide adenine dinucleotide phosphate (NADPH). Although this assay has been adequate to study the biology of these enzymes, it is not amenable to support any degree of routine inhibitor assessment because its restricted linearity is incompatible with enhanced throughput microtiter plate screening. In this article, we report the development and validation of a nonenzymatically coupled screening assay in which the product of the enzymatic reaction reduces cytochrome <italic>c,</italic> causing an increase in absorbance at 550 nm. We demonstrate this assay to be robust and accurate, and we describe its utility in supporting a structure-based design, small-molecule inhibitor campaign against <italic>Trypanosoma brucei</italic> PTR1 and DHFR-TS.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Drug discovery</kwd>
        <kwd>Screening</kwd>
        <kwd>Pteridine reductase</kwd>
        <kwd>Dihydrofolate reductase</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Human African trypanosomiasis (HAT),<xref rid="fn1" ref-type="fn">1</xref> also known as sleeping sickness, is a protozoan parasitic disease that causes death and disability across large undeveloped regions of sub-Saharan Africa <xref rid="bib1" ref-type="bibr">[1]</xref>. Infection is caused by two subspecies of <italic>Trypanosoma brucei</italic>: <italic>T. b. gambiense</italic> (endemic in central and western areas) and <italic>T. b. rhodesiense</italic> (predominantly found in southern and eastern Africa). Both infections are fatal if left untreated. The early (hemolymphatic) stage of the disease is treated by suramin or pentamidine, and the late (central nervous system) stage is treated by eflornithine (<italic>T. b. gambiense</italic>) or the arsenical drug melarsoprol (both forms). All currently available drugs must be given by injection and suffer from serious deficiencies such as unacceptable toxicity, poor efficacy, high cost, and the need for prolonged hospitalization.</p>
    <p>Development of drug therapies for HAT has been largely disregarded over the past 60 years. Investment in drug discovery for this and other “orphan” diseases has declined sufficiently such that less than 1% of all new drugs over the past 25 years have targeted tropical parasitic diseases <xref rid="bib2" ref-type="bibr">[2]</xref>. This is largely due to the poverty associated with these neglected diseases and the consequent low profitability of developing and manufacturing drugs.</p>
    <p>Pterins and folates are known to be essential for growth in <italic>Leishmania</italic> spp. and related trypanosomatids <xref rid="bib3 bib4" ref-type="bibr">[3,4]</xref>, and biosynthetic enzymes for de novo synthesis are lacking from their respective genomes <xref rid="bib5" ref-type="bibr">[5]</xref>. Consequently, trypanosomatids possess multiple biopterin and folate transporters with salvage pathways to convert them into the reduced cofactors 5,6,7,8-tetrahydrobiopterin (H<sub>4</sub>B) and 5,6,7,8-tetrahydrofolate (H<sub>4</sub>F) by means of pteridine reductase 1 (PTR1, EC 1.5.1.33) and the bifunctional, nicotinamide adenine dinucleotide phosphate (NADPH)-dependent enzyme dihydrofolate reductase–thymidylate synthase (DHFR-TS, ECs 1.5.1.4 and 2.1.1.45, respectively). Due to the auxotrophic nature of these parasites for folates and pterins, the enzymes associated with their metabolism have been investigated extensively as potential drug targets <xref rid="bib3 bib4" ref-type="bibr">[3,4]</xref>.</p>
    <p>DHFR-TS, together with serine hydroxymethyltransferase (SHMT) or the glycine cleavage system (the former enzyme is present in <italic>Leishmania major</italic> but not in <italic>T. brucei</italic> <xref rid="bib5 bib6" ref-type="bibr">[5,6]</xref>), is responsible for de novo synthesis of thymidylate (dTMP) required for DNA replication. Gene knockout studies indicate that <italic>dhfr-ts</italic> null mutants of <italic>L. major</italic> and <italic>T. brucei</italic> are able to grow normally in culture provided that thymidine is present in the medium <xref rid="bib7 bib8" ref-type="bibr">[7,8]</xref>. <italic>T. brucei</italic> DHFR-TS null mutants are unable to establish an infection in mice due to the extremely low concentrations of thymidine in plasma <xref rid="bib8" ref-type="bibr">[8]</xref>. In contrast, <italic>L. major</italic> DHFR-TS null mutants cause low-grade infections in mice <xref rid="bib9" ref-type="bibr">[9]</xref>, presumably due to limited availability of thymidine in the infected macrophage.</p>
    <p>Disappointingly, DHFR-TS inhibitors, such as those commonly used in the development of anticancer, antimalarial, and antibacterial drugs, have not shown equivalent efficacy against <italic>T. brucei</italic> <xref rid="bib8" ref-type="bibr">[8]</xref><italic>.</italic> As demonstrated elegantly by Beverley and coworkers for <italic>L. major</italic> <xref rid="bib10 bib11" ref-type="bibr">[10,11]</xref>, PTR1, a broad-specificity, short-chain dehydrogenase, can reduce dihydrofolate (H<sub>2</sub>F) to H<sub>4</sub>F, thereby circumventing inhibition of DHFR-TS. Therefore, it is likely that cooperative inhibition of both trypanosomal enzymes may be required to produce an effective therapy.</p>
    <p>It is also possible that PTR1 may be a therapeutic target in its own right given that its primary function is to sequentially reduce biopterin (B) to 7,8-dihydrobiopterin (H<sub>2</sub>B) and H<sub>4</sub>B. The biological function of pterins in trypanosomatids is unknown, and many functions reported for mammalian cells have been discounted <xref rid="bib3 bib12 bib13" ref-type="bibr">[3,12,13]</xref>. <italic>L. major</italic> <italic>ptr1</italic><sup>−</sup> mutants are viable provided that the medium is supplemented with H<sub>2</sub>B and H<sub>4</sub>B <xref rid="bib10 bib14" ref-type="bibr">[10,14]</xref>. However, similar gene knockout and knockdown studies on bloodstream <italic>T. brucei</italic> suggest that PTR1 is essential (N. Sienkiewicz and A. H. Fairlamb, unpublished).</p>
    <p>The Drug Discovery Unit at the University of Dundee has been established to undertake a fully integrated approach to neglected disease drug discovery. Combining a variety of approaches to hit discovery, including high-throughput screening, ligand- and structure-based design with medicinal chemistry, and drug metabolism and pharmacokinetics (DMPK) capabilities, our goal is to deliver drug candidates for HAT for entry into formal preclinical development. To support this endeavor, a portfolio of targets has been compiled and assessed <xref rid="bib15" ref-type="bibr">[15]</xref> at Dundee from worldwide research efforts, with <italic>T. brucei</italic> DHFR-TS (<italic>Tb</italic>DHFR-TS) and <italic>T. brucei</italic> PTR1 (<italic>Tb</italic>PTR1) ranking high on this prioritized list.</p>
    <p>The assay principally used for measuring DHFR-TS and PTR1 activity follows a spectrophotometric decrease in absorbance at 340 nm, corresponding to oxidation of NADPH in the presence of H<sub>2</sub>F and H<sub>2</sub>B (or biopterin), respectively. However, this cuvette-based assay is unsuitable for supporting any level of throughput with the necessary robustness required to support a progressive medicinal chemistry effort. Similarly, detection of enzyme activity by high-performance liquid chromatography (HPLC) also presents insufficient throughput.</p>
    <p>The development of a screening assay to support in vitro target activity assessment that provides relevant accurate data and performs consistently throughout a program contributes significantly to the success of a lead development project. Therefore, a robust “fit for purpose” assay is a necessity in discovering initial chemical starting points and the subsequent development of meaningful structure–activity relationships for compound series. To enable routine screening for small-molecule inhibitors of <italic>Tb</italic>DHFR-TS and <italic>Tb</italic>PTR1, we developed and validated a nonenzymatically coupled absorbance assay. Here the enzymatic products H<sub>4</sub>B and H<sub>4</sub>F are coupled to the reduction of oxidized cytochrome <italic>c</italic> (cyt <italic>c</italic> Fe<sup>3+</sup>), the formation of which can be measured as an increase in absorbance at 550 nm. The assay is executed in a 96-well microtiter plate, with performance statistics commensurate with the long-term support of a medicinal chemistry program.</p>
    <sec sec-type="materials|methods">
      <title>Materials and methods</title>
      <sec>
        <title>Cloning and protein production of <italic>Tb</italic>PTR1 and <italic>Tb</italic>DHFR-TS</title>
        <p>All plasmids used were sequenced by the University of Dundee DNA Sequencing Service (<ext-link xlink:href="http://www.dnaseq.co.uk" ext-link-type="uri">http://www.dnaseq.co.uk</ext-link>) and verified against the published database sequences.</p>
        <p><italic>Tb</italic>PTR1 was expressed and purified as the N-terminal hexahistidine-tagged protein as described previously <xref rid="bib16" ref-type="bibr">[16]</xref>.</p>
        <p>The 1584-nucleotide sequence (accession no. TBU20781) encoding the full-length <italic>Tb</italic>DHFR-TS was obtained by polymerase chain reaction (PCR) from <italic>T. brucei</italic> strain 427 genomic DNA (kindly provided by M. Lucia L. Güther, University of Dundee) using the forward primer 5′-CT<underline>GGATCC</underline>ATGCTCAGTCTTACGCGTATCCTCCG-3′ and the reverse primer 5′-GA<underline>CTCGAG</underline>CTACACCGCCATCTCCATAGAAATTACG-3′. The underlined bases represent restriction sites for <italic>Bam</italic>HI and <italic>Xho</italic>I, respectively, and were used for cloning into a pFastBac1 bacculovirus expression vector (Invitrogen) that had been modified to encode a glutathione <italic>S</italic>-transferase (GST) tag followed by a PreScission protease recognition sequence, resulting in the final bacculovirus expression construct pFastBac GST–<italic>Tb</italic>DHFR-TS. Recombinant protein was produced using the Bac-to-Bac system (Invitrogen) following the manufacturer’s protocol. Bacculovirus at a multiplicity of infection of 5 was used to infect <italic>Spodoptera frugiperda</italic> 21 cells (1.5 × 10<sup>6</sup>/ml). The infected cells were harvested 48 h postinfection, and the GST-tagged protein was purified on glutathione (GSH)–Sepharose (GE Healthcare). <italic>Tb</italic>DHFR-TS was unstable on cleavage of the GST tag; therefore, all experiments were carried out using GST-tagged protein.</p>
      </sec>
      <sec>
        <title>Determination of enzyme concentration</title>
        <p><italic>Tb</italic>PTR1 enzyme concentration was determined spectrophotometrically (extinction coefficient at 260 nm = 14,815 M<sup>−1</sup> cm<sup>−1</sup>). Because tightly bound folate can interfere with absorbance at 260 and 280 nm, the concentration of <italic>Tb</italic>DHFR-TS was determined using Coomassie blue reagent <xref rid="bib17" ref-type="bibr">[17]</xref>.</p>
        <p>The concentration of catalytically active enzyme in each preparation was determined using a titration of enzyme in the presence of excess inhibitor, methotrexate (MTX), to calculate the concentration of active sites in each sample. This concentration was used for all subsequent work.</p>
      </sec>
      <sec>
        <title>Novel screening assay protocol: Assay conditions</title>
        <p><italic>Tb</italic>PTR1 activity was assayed in a buffer containing 20 mM sodium citrate and 1 mM ethylenediaminetetraacetic acid (EDTA) (pH 6.0). The final reaction mixture contained test compound at a range of concentrations: <italic>Tb</italic>PTR1 (4.8 nM), H<sub>2</sub>B (0.35 μM), cyt <italic>c</italic> (81 μM), and NADPH (100 μM). The final assay volume was 200 μl in 96-well clear polystyrene plates with a final dimethyl sulfoxide (DMSO) level of 1% in all samples, including controls.</p>
        <p><italic>Tb</italic>DHFR-TS activity was assayed in a buffer containing 20 mM sodium citrate and 1 mM EDTA (pH 7.4). The final reaction mixture contained test compound at a range of concentrations: <italic>Tb</italic>DHFR-TS (1 nM), H<sub>2</sub>F (4.4 μM), cyt <italic>c</italic> (81 μM), and NADPH (100 μM). The final assay volume was 200 μl in 96-well clear polystyrene plates with a final DMSO level of 1% in all samples, including controls.</p>
        <p>All reagents were solubilized in assay buffer with the exception of H<sub>2</sub>B, which was solubilized in 0.2 M NaOH. The final assay concentration of NaOH was 70 μM.</p>
      </sec>
      <sec>
        <title>Novel screening assay protocol: Liquid handling</title>
        <p>Test and standard compounds were cherry-picked into the first column of a 96-well polypropylene plate and then serially diluted in 100% DMSO through 10 half-log increments in row orientation using a JANUS eight-channel Varispan automated workstation (PerkinElmer). This produced working stock (100× final concentration in assay) compound plates with six test compound curves and two standard compound curves occupying columns 1 to 10. Aliquots (2 μl) of each compound working stock were then stamped into replicate clear 96-well polystyrene assay plates using a PlateMate 2 × 2 pipetting workstation (Thermo Fisher).</p>
        <p>Then 20 μl of cyt <italic>c</italic> (stock concentration of 810 μM in assay buffer) was added to all wells using the JANUS MDT I200 96-well head (PerkinElmer). Assay buffer (176 μl) containing enzyme and substrate (stock concentrations of 5.5 nM and 0.4 μM for <italic>Tb</italic>PTR1 and 1.12 nM and 5 μM for <italic>Tb</italic>DHFR-TS, respectively) was then added to columns 1 to 11 only using the same instrument. Buffer containing substrate only was added to column 12 to provide the no-enzyme control. In all liquid handling steps for reagent addition, tips were washed between each transfer and changed after two transfers.</p>
        <p>The reaction was started by the addition of 2 μl of NADPH (stock concentration of 100 μM) using a FlexDrop reagent dispenser (PerkinElmer). Each plate was started at 1-min intervals in accordance with the time taken to read a plate. The <italic>Tb</italic>PTR1 assay was run for 50 min, the <italic>Tb</italic>DHFR assay was run for 40 min, and the absorbance was read at 550 nm using a Victor<sup>3</sup> multilabel plate reader (PerkinElmer).</p>
      </sec>
      <sec>
        <title>Spectrophotometric assay for <italic>Tb</italic>PTR1</title>
        <p>Verification of catalytic activity of <italic>Tb</italic>PTR1 was carried out as described by Dawson and coworkers <xref rid="bib16" ref-type="bibr">[16]</xref>. Briefly, solutions containing <italic>Tb</italic>PTR1 (82.5 nM) and H<sub>2</sub>B (20 μM in 0.2 M NaOH) were buffered with 20 mM sodium citrate (pH 4.7). The reaction was executed in a 1-ml cuvette (990 μl) and initiated with 100 μM NADPH (10 μl). A decrease in absorbance was followed spectrophotometrically at 340 nm.</p>
      </sec>
      <sec>
        <title>HPLC assay for <italic>Tb</italic>PTR1</title>
        <p><italic>Tb</italic>PTR1 activity was assayed by directly measuring the formation of H<sub>4</sub>B from H<sub>2</sub>B at 22 °C using a previously described HPLC-based method <xref rid="bib18" ref-type="bibr">[18]</xref> with modifications. Assays were carried out in 20 mM sodium citrate (pH 6.0) (for direct comparison with the screening assay) containing 1 mM EDTA and 50 μM NADPH cofactor. Aliquots (100 μl) of enzymatic reactions were made alkaline by the addition of 46 mM NaOH and oxidized in the presence of 12 mM KI/4.4 mM I<sub>2</sub> in the dark at 22 °C for 1 h. Under these conditions, H<sub>2</sub>B and H<sub>4</sub>B were oxidized to biopterin and pterin, respectively <xref rid="bib18 bib19" ref-type="bibr">[18,19]</xref>. Excess iodine was removed by the addition of 12 mM ascorbate. Neopterin (25 nM) was added as internal standard. Samples were then acidified with 83 mM HCl, and precipitated proteins were removed by centrifugation (16,000<italic>g,</italic> 10 min, 22 °C). Supernatants were analyzed by reverse-phase HPLC on an ion-paired Ultrasphere C<sub>18</sub> column using a Dionex UltiMate 3000 system coupled to a Dionex RF-2000 fluorometer. The mobile phase contained 20 mM sodium phosphate and 4 to 10% methanol with a flow rate of 1 ml min<sup>−1</sup>. Pterins were detected fluorometrically using excitation and emission wavelengths of 360 and 440 nm, respectively. Products were quantified against pterin standards whose concentrations were determined using published extinction coefficients <xref rid="bib20" ref-type="bibr">[20]</xref>. The linearity of the assay was established by measuring H<sub>4</sub>B formation over time (15–180 s) in the presence of 1.1 nM <italic>Tb</italic>PTR1 using 10 and 500 nM H<sub>2</sub>B. The enzyme proportionality of the assay was investigated by measuring H<sub>4</sub>B produced in 1 min by varying concentrations of <italic>Tb</italic>PTR1 (0.31–10 nM) using constant substrate (25 nM H<sub>2</sub>B). The linearity of the data sets was analyzed by linear regression. The <italic>K</italic><sub>m</sub> for H<sub>2</sub>B was determined by measuring H<sub>4</sub>B produced in 1 min by 1.1 nM <italic>Tb</italic>PTR1 using varying concentrations of H<sub>2</sub>B (3–300 nM). The IC<sub>50</sub> for MTX was determined by measuring H<sub>4</sub>B produced in 1 min by 1.1 nM <italic>Tb</italic>PTR1 at [<italic>S</italic>] = <italic>K</italic><sub>m</sub> in the presence of varying concentrations of MTX.</p>
      </sec>
      <sec>
        <title>Crystallography</title>
        <p>In preparation for crystallization, <italic>Tb</italic>PTR1 was concentrated to 6 mg ml<sup>−1</sup> in 20 mM Tris–HCl (pH 8.0). The ligand DDD00066641 was solubilized to a concentration of 200 mM in DMSO. The ternary complex of <italic>Tb</italic>PTR1 with cofactor and ligand was prepared by incubating the protein solution (6 mg ml<sup>−1</sup>) with 2 mM of the ligand, 1 mM NADP<sup>+</sup>, and 20 mM dithiothreitol in 20 mM Tris–HCl (pH 8.0) at 4 °C for 30 min prior to crystallization.</p>
        <p>Crystallization was carried out by the vapor diffusion method by mixing 2 μl of the protein solution with 2 μl of the reservoir solution and incubating the drops over 100 μl of the reservoir in sitting drop plates. The reservoir solution consisted of 1.5–3.0 M Na acetate and 0.1 M citrate buffer (pH 4.5–6.0). Diffraction quality crystals were obtained after incubation for 2 to 3 days at 18 °C.</p>
        <p>Diffraction data were collected using a rotating anode X-ray source (Rigaku Micromax 007) and an image plate detector (Rigaku R-AXIS IV<sup>++</sup>). Crystals were prepared for data collection by transferring them through a cryoprotection solution of mother liquor plus 20% glycerol and then were flash frozen in a stream of gaseous nitrogen at 100 K. Data were integrated and scaled using MOSFLM <xref rid="bib21" ref-type="bibr">[21]</xref> and SCALA <xref rid="bib22" ref-type="bibr">[22]</xref> from the CCP4 <xref rid="bib23" ref-type="bibr">[23]</xref> suite of programs.</p>
        <p>Molecular replacement, as implemented in MOLREP <xref rid="bib24" ref-type="bibr">[24]</xref>, was used to solve the structure using the protein chains from the <italic>Tb</italic>PTR1/MTX complex <xref rid="bib16" ref-type="bibr">[16]</xref> (Protein Data Bank [PDB] 2C7V) as the starting model. After the molecular replacement step, a round of rigid body refinement was carried out using REFMAC5 <xref rid="bib25" ref-type="bibr">[25]</xref>. Ligand models and associated topology files were created with PRODRG <xref rid="bib26" ref-type="bibr">[26]</xref> and were built into F<sub>o</sub> − F<sub>c</sub> electron density maps using COOT <xref rid="bib27" ref-type="bibr">[27]</xref>. Further rounds of restrained refinement were carried out using REFMAC5 and manual alteration of the models, including the addition of solvent molecules using COOT. Coordinates and structure factors for <italic>Tb</italic>PTR1 plus DDD000066641 have been deposited in the PDB with accession code 2VZ0.</p>
      </sec>
      <sec>
        <title>Data analysis</title>
        <p>For determination of <italic>K</italic><sub>m</sub>, data were fitted by nonlinear regression in GraFit to the following general equation for substrate inhibition:<disp-formula id="fd1"><label>(1)</label><mml:math id="M1" altimg="si1.gif" overflow="scroll"><mml:mi>ν</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mtext>max</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mtext>m</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mtext>i</mml:mtext></mml:mrow><mml:mrow><mml:mtext>S</mml:mtext></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:mfrac><mml:mtext>.</mml:mtext></mml:math></disp-formula></p>
        <p>For determination of IC<sub>50</sub> for inhibitors, all routine curve fitting was undertaken using a four-parameter logistic dose–response curve (model 205) in XLFit 4.2.</p>
        <p>For MTX potency determination, data were fitted in GraFit to Morrison’s quadratic equation for tight-binding inhibitors <xref rid="bib28" ref-type="bibr">[28]</xref>:<disp-formula id="fd2"><label>(2)</label><mml:math id="M2" altimg="si2.gif" overflow="scroll"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>ν</mml:mi></mml:mrow><mml:mrow><mml:mtext>i</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>ν</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mtext>T</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>I</mml:mi><mml:msub><mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mtext>T</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mtext>i</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:mrow></mml:mfenced></mml:mrow><mml:mo>-</mml:mo><mml:msqrt><mml:mrow><mml:msup><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mtext>T</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>I</mml:mi><mml:msub><mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mtext>T</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mtext>i</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:mn>4</mml:mn><mml:mo stretchy="false">[</mml:mo><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mtext>T</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">[</mml:mo><mml:mi>I</mml:mi><mml:msub><mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mtext>T</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:msqrt></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo stretchy="false">[</mml:mo><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mtext>T</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mtext>,</mml:mtext></mml:math></disp-formula></p>
        <p>where <italic>v</italic><sub>i</sub> and <italic>v</italic><sub>0</sub> are the rates with and without inhibitor, [<italic>E</italic>]<sub>T</sub> is the total enzyme concentration (a fixed parameter), [<italic>I</italic>]<sub>T</sub> is the total inhibitor concentration, and <italic>K</italic><sub>i</sub><sup>app</sup> is the apparent inhibitor constant.</p>
        <p>For competitive inhibitors,<disp-formula id="fd3"><label>(3)</label><mml:math id="M3" altimg="si3.gif" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mtext>i</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mtext>i</mml:mtext></mml:mrow></mml:msub><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mtext>m</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow><mml:mtext>.</mml:mtext></mml:math></disp-formula></p>
        <p>For routine assessment of potency for tight-binding inhibitors identified through test compounds, <italic>BatchK<sub>i</sub></italic> software (BioKin) was used to determine <italic>K</italic><sub>i</sub><sup>app</sup>. A modified Morrison equation <xref rid="bib29" ref-type="bibr">[29]</xref> was used as the fitting model in which <italic>v</italic><sub>b</sub> is the background enzymatic rate, <italic>v</italic><sub>0</sub> is the “full” catalytic signal in the absence of inhibitor, [<italic>E</italic>]<sub>0</sub> is the active enzyme concentration, and [<italic>I</italic>]<sub>T</sub> is the inhibitor concentration:<disp-formula id="fd4"><label>(4)</label><mml:math id="M4" altimg="si4.gif" overflow="scroll"><mml:mi>ν</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>ν</mml:mi></mml:mrow><mml:mrow><mml:mtext>b</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>ν</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mfrac><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>I</mml:mi><mml:msub><mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mtext>T</mml:mtext></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mtext>i</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msqrt><mml:mrow><mml:msup><mml:mrow><mml:mfenced open="(" close=")"><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>I</mml:mi><mml:msub><mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mtext>T</mml:mtext></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mtext>i</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:mn>4</mml:mn><mml:mo stretchy="false">[</mml:mo><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mtext>i</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:mrow></mml:msqrt></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo stretchy="false">[</mml:mo><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mtext>.</mml:mtext></mml:math></disp-formula></p>
        <p>The <italic>BatchK<sub>i</sub></italic> software automatically determined initial estimates of <italic>K</italic><sub>i</sub><sup>app</sup> based on a weighted average algorithm <xref rid="bib30" ref-type="bibr">[30]</xref>. First-round analysis treated the active enzyme concentration as a fixed constant and treated <italic>v</italic><sub>b</sub>, <italic>v</italic><sub>0</sub>, and <italic>K</italic><sub>i</sub><sup>app</sup> as adjustable parameters. For tight-binding inhibitors, a second round of analysis allowed determination of the enzyme active site concentration, where [<italic>E</italic>]<sub>0</sub> is treated as an adjustable parameter <xref rid="bib31" ref-type="bibr">[31]</xref>. The optimization of [<italic>E</italic>]<sub>0</sub> was performed within preset limits (±5∗[<italic>E</italic>]<sub>0</sub>). The data-fitting algorithm used in <italic>BatchK<sub>i</sub></italic> software was either Reich’s modification <xref rid="bib32" ref-type="bibr">[32]</xref> of the Levenberg–Marquardt method <xref rid="bib33" ref-type="bibr">[33]</xref> or a robust regression algorithm <xref rid="bib34" ref-type="bibr">[34]</xref> based on Huber’s minimax method <xref rid="bib35" ref-type="bibr">[35]</xref>.</p>
        <p>The <italic>Z</italic>′ factor for control data on each screening plate was calculated as defined by Zhang and coworkers <xref rid="bib36" ref-type="bibr">[36]</xref>, where μ<sub>HI</sub> and μ<sub>LO</sub> are the means and σ<sub>HI</sub> and σ<sub>LO</sub> are the standard deviations for the positive and negative control wells, respectively:<disp-formula id="fd5"><label>(5)</label><mml:math id="M5" altimg="si5.gif" overflow="scroll"><mml:msup><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mfrac><mml:mrow><mml:mn>3</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">σ</mml:mi></mml:mrow><mml:mrow><mml:mtext>HI</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">σ</mml:mi></mml:mrow><mml:mrow><mml:mtext>LO</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">μ</mml:mi></mml:mrow><mml:mrow><mml:mtext>HI</mml:mtext></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mi mathvariant="normal">μ</mml:mi><mml:mtext>LO</mml:mtext></mml:mrow></mml:mfrac><mml:mtext>.</mml:mtext></mml:math></disp-formula></p>
      </sec>
    </sec>
    <sec>
      <title>Results</title>
      <sec>
        <title>Reduction of cyt <italic>c</italic> Fe<sup>3+</sup> as a read-out of PTR1 activity in vitro</title>
        <p>Previously, Hasegawa and coworkers <xref rid="bib37" ref-type="bibr">[37]</xref> demonstrated that H<sub>4</sub>B could be oxidized by ferricytochrome <italic>c</italic> (cyt <italic>c</italic> Fe<sup>3+</sup>) via a trihydrobiopterin radical intermediate to form quinonoid H<sub>2</sub>B (qH<sub>2</sub>B) and cyt <italic>c</italic> Fe<sup>2+</sup> (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). The formation of reduced cyt <italic>c</italic> Fe<sup>2+</sup> can be monitored as an increase in absorbance at 550 nm. Therefore, we investigated whether this reaction could be adopted to enable detection of the product of the PTR1 and DHFR-TS enzyme reactions.</p>
        <p>We first determined “proof of concept” for the coupling assay using a standard ultraviolet–visible (UV–Vis) spectrophotometer (<xref rid="fig2" ref-type="fig">Fig. 2</xref>A). The absorbance profile of cyt <italic>c</italic> Fe<sup>3+</sup> and cyt <italic>c</italic> Fe<sup>2+</sup> was determined. Cyt <italic>c</italic> Fe<sup>2+</sup> produced by an excess of solid sodium dithionite was confirmed to be a narrow defined peak at 550 nm, accompanied by the formation of an additional shallower and broader peak at 520 nm. A similar spectrum was obtained on reduction with H<sub>4</sub>B but not with H<sub>2</sub>B (not shown). However, H<sub>2</sub>B was able to reduce cyt <italic>c</italic> Fe<sup>3+</sup> in the presence of <italic>Tb</italic>PTR1 and NADPH in a time-dependent manner (<xref rid="fig2" ref-type="fig">Fig. 2</xref>A).</p>
      </sec>
      <sec>
        <title>Development of a microtiter plate-based screening assay</title>
        <p>From this point forward, all work was carried out in a 96-well plate format with a Victor<sup>3</sup> multilabel plate reader (PerkinElmer) using a 550 ± 9-nm filter. The optimum pH for the coupled assay was determined to be pH 6.0 in either citrate or phosphate buffer (<xref rid="fig2" ref-type="fig">Fig. 2</xref>B). Cyt <italic>c</italic> concentrations greater than 50 μM gave maximal rates of reduction (<xref rid="fig2" ref-type="fig">Fig. 2</xref>C), and rates of cyt <italic>c</italic> reduction are proportional to enzyme activity up to 25 nM (<xref rid="fig2" ref-type="fig">Fig. 2</xref>D).</p>
        <p>Following a lag period, reduction of cyt <italic>c</italic> was linear from 20 to 60 min (<italic>r</italic><sup>2</sup> = 0.9994) and, therefore, was suitable for kinetic analyses (<xref rid="fig3" ref-type="fig">Fig. 3</xref>). The increase in <italic>A</italic><sub>550nm</sub> over this period in the absence of <italic>Tb</italic>PTR1 was negligible and indicates that NADPH itself does not significantly reduce cyt <italic>c.</italic> For routine inhibitor screening, plates were read after 50 min to ensure that a maximal signal was achieved. At this time point, 23.9 μM of product (cyt <italic>c</italic> Fe<sup>2+</sup>) had been formed from 0.35 μM H<sub>2</sub>B in the reaction mixture. Based on the stoichiometry of 1.5 to 1.8 for reduction of cyt <italic>c</italic> by H<sub>4</sub>B under aerobic conditions, H<sub>2</sub>B had been cycled 40–46 times after 50 min, and measuring linear rates of reaction between 20 and 50 min, the signal-to-background ratio for the assay was determined to be 43. Given that not more than 10% of H<sub>2</sub>B can be used in the direct assay, when measuring the initial linear rate of absorbance change at 340 nm due to the oxidation of NADPH, it is evident that the coupled assay is approximately 400-fold more sensitive than the direct assay method.</p>
        <p>Termination of the reaction can be achieved with 10 μl of NaOH (0.2 mM), although use of a rapid read plate reader dispensed with the need for this additional step in our studies. Initial performance statistics of the microtiter plate-based assay demonstrated its clear potential for routine compound assessment purposes, yielding highly acceptable <italic>Z</italic>′ values (<xref rid="tbl1" ref-type="table">Table 1</xref>).</p>
      </sec>
      <sec>
        <title>Determination of kinetic parameters</title>
        <p>Using the coupled assay, the linear rate of product formation was measured over a wide range of H<sub>2</sub>B concentrations. The resulting plot of rate versus substrate concentration revealed pronounced inhibition by H<sub>2</sub>B (<xref rid="fig4" ref-type="fig">Fig. 4</xref>), as reported previously for the <italic>T. brucei</italic> <xref rid="bib16" ref-type="bibr">[16]</xref> and <italic>L. major</italic> enzymes <xref rid="bib11" ref-type="bibr">[11]</xref>. Fitting the data to the standard equation for substrate inhibition (Eq. <xref rid="fd1" ref-type="disp-formula">(1)</xref>) gave an apparent <italic>K</italic><sub>m</sub> (<italic>K</italic><sub>m</sub><sup>app</sup>) of 151 ± 50 nM, a substrate inhibition constant (<italic>K</italic><sub>i</sub><sup>s</sup>) of 439 ± 135 nM, and a <italic>k</italic><sub>cat</sub> of 0.0016 ± 0.0003 s<sup>−1</sup>. These kinetic parameters are considerably lower than those reported previously <xref rid="bib16" ref-type="bibr">[16]</xref> but were determined at pH 6.0 (optimal in this assay format) rather than at the previously reported pH optimum of 3.7.</p>
        <p>To confirm the validity of the coupled assay, kinetic parameters with respect to substrate were also determined using an alternative HPLC-based assay for PTR1 activity determination (<xref rid="fig5" ref-type="fig">Fig. 5</xref>). Using this method, formation of H<sub>4</sub>B product was stoichiometric with the disappearance of H<sub>2</sub>B, linear for at least 2 min across the assay range (<xref rid="fig5" ref-type="fig">Fig. 5</xref>A), and rates determined after 1 min of incubation were proportional to enzyme up to at least 5 nM <italic>Tb</italic>PTR1 (<italic>r</italic><sup>2</sup> = 0.9999) (<xref rid="fig5" ref-type="fig">Fig. 5</xref>B). As noted previously, the enzyme is inhibited at high substrate concentrations, yielding kinetic parameters <italic>K</italic><sub>m</sub><sup>app</sup> = 25 ± 6.7 nM, <italic>K</italic><sub>i</sub><sup>s</sup> = 37.2 ± 10.4 nM, and <italic>k</italic><sub>cat</sub> = 0.070 ± 0.013 s<sup>−1</sup> (<xref rid="fig5" ref-type="fig">Fig. 5</xref>C and D). The 7-fold discrepancy in <italic>K</italic><sub>m</sub><sup>app</sup> between the coupled recycling assay and the HPLC assay most likely reflects the fact that, under steady-state conditions in the coupled assay, the biopterin substrate is present as a mixture of H<sub>2</sub>B, H<sub>4</sub>B, and qH<sub>2</sub>B (see <xref rid="fig1" ref-type="fig">Fig. 1</xref>).</p>
        <p>For standard inhibitor screening, it is ideal to run an assay at or below <italic>K</italic><sub>m</sub> for competing substrate to maximize the chances of identifying activity. However with significant substrate inhibition and limited signal-to-background ratio in this assay, an H<sub>2</sub>B concentration giving an optimal window of signal in the coupled assay was selected for routine screening. The second substrate, NADPH, was saturating in both assays given that the <italic>K</italic><sub>m</sub><sup>app</sup> is 1.6 ± 0.1 μM, as determined by the HPLC assay method (data not shown).</p>
        <p>Based on these studies, the final optimized assay conditions used for compound screening were defined as 0.3 μM H<sub>2</sub>B, 100 μM NADPH, 81 μM cyt <italic>c</italic> Fe<sup>3+</sup>, and 4.8 nM <italic>Tb</italic>PTR1 in 20 mM sodium citrate buffer plus 1 mM EDTA (pH 6.0). These conditions were expected to be conducive to the identification of inhibitors binding at the substrate site of <italic>Tb</italic>PTR1.</p>
      </sec>
      <sec>
        <title>Inhibition by MTX</title>
        <p>Further validation of the coupled assay was obtained through the use of the established antifolate MTX as a standard inhibitor. An average IC<sub>50</sub> of 13.7 ± 2.1 nM (<italic>n</italic> = 16) and a Hill slope of 1.19 ± 0.14 (<italic>n</italic> = 16) were determined using the newly developed screening assay (<xref rid="fig6" ref-type="fig">Fig. 6</xref>A). Given the enzyme concentration (4.8 nM), MTX potency is within tight-binding territory <xref rid="bib38" ref-type="bibr">[38]</xref>. Therefore, <italic>K</italic><sub>i</sub><sup>app</sup> analysis was undertaken to report potencies more accurately (Eq. <xref rid="fd2" ref-type="disp-formula">(2)</xref>). The corresponding <italic>K</italic><sub>i</sub><sup>app</sup> was 11.1 ± 2.1 nM. MTX potency against <italic>Tb</italic>PTR1 was validated using the HPLC assay, yielding an IC<sub>50</sub> of 8.2 ± 0.2 nM and a <italic>K</italic><sub>i</sub><sup>app</sup> of 7.1 ± 1.0 nM. Based on the <italic>K</italic><sub>m</sub><sup>app</sup> and H<sub>2</sub>B concentrations used in the respective assays (Eq. <xref rid="fd3" ref-type="disp-formula">(3)</xref>), the <italic>K</italic><sub>i</sub> values for MTX were in excellent agreement (4.1 and 3.6 nM for the coupled and HPLC assays, respectively).</p>
        <p>Furthermore, <xref rid="fig6" ref-type="fig">Fig. 6</xref>B shows a typical concentration–effect curve in the screening assay for a compound representing one of the novel chemical series identified through our medicinal chemistry efforts.</p>
      </sec>
      <sec>
        <title>Assay development for <italic>Tb</italic>DHFR-TS</title>
        <p>To produce an effective therapy for HAT, it is possible that inhibition of both <italic>Tb</italic>PTR1 and <italic>Tb</italic>DHFR-TS will be required. Therefore, the application of the coupled assay to measure DHFR activity in vitro was investigated. The coupled assay format was found to support the measurement of both human and <italic>Tb</italic>DHFR-TS activity, in particular using a sodium citrate buffer (pH 7.4) to optimize the window of signal achievable.</p>
        <p>Under these conditions, activity was proportional up to at least 15 nM <italic>Tb</italic>DHFR-TS (<xref rid="fig7" ref-type="fig">Fig. 7</xref>A) and the assay was linear between approximately 2 and 55 min. The enzyme displayed normal Michaelis–Menten kinetics, with H<sub>2</sub>F as substrate yielding a <italic>K</italic><sub>m</sub><sup>app</sup> of 7.3 ± 1.5 μM (<xref rid="fig7" ref-type="fig">Fig. 7</xref>B and C). MTX was shown to be a very potent inhibitor of <italic>Tb</italic>DHFR-TS, with an average IC<sub>50</sub> of 0.64 nM ± 0.28 nM and an average Hill slope of 0.78 ± 0.08 (<italic>n</italic> = 16) (<xref rid="fig7" ref-type="fig">Fig. 7</xref>D). Because MTX proved to be a tight-binding inhibitor of <italic>Tb</italic>DHFR-TS, the corresponding <italic>K</italic><sub>i</sub><sup>app</sup> was calculated for MTX to be 0.24 ± 0.14 nM, yielding a <italic>K</italic><sub>i</sub> of 0.15 nM.</p>
        <p>The assay performance statistics generated from assay development and mock screening studies for the DHFR assay are shown in <xref rid="tbl1" ref-type="table">Table 1</xref>. As for the PTR1 assay, they yielded readily acceptable <italic>Z</italic>′ values.</p>
      </sec>
      <sec>
        <title>Lead generation for <italic>Tb</italic>DHFR-TS and <italic>Tb</italic>PTR1</title>
        <p>The program was initiated using two approaches: ligand-based design and in silico screening. The identification and optimization of PTR1 and DHFR-TS inhibitory activity were underpinned by data provided by the newly developed screening assay and structure-guided chemistry design. Throughout the project, potency values (<italic>K</italic><sub>i</sub><sup>app</sup> from 10-point concentration–effect curves, <italic>n</italic> = 2) were generated for <italic>Tb</italic>PTR1, <italic>Tb</italic>DHFR-TS, and (for selectivity purposes) human DHFR (Eq. <xref rid="fd4" ref-type="disp-formula">(4)</xref>). <xref rid="fig8" ref-type="fig">Fig. 8</xref> illustrates the high level of correlation observed between replicate potency values for a sample of test compounds in both PTR1 and DHFR-TS assays. These data provided early confidence that the assay developed could robustly support the development of structure–activity relationships for the compound series investigated. <xref rid="fig8" ref-type="fig">Fig. 8</xref>C illustrates the highly consistent performance of the PTR1 assay with respect to the key metrics of <italic>Z</italic>′ and MTX potency over a time period spanning 18 months. The ultimate validation of this novel screening assay was confirmed on demonstration that compounds identified as actives using the new assay were in fact legitimately binding to <italic>Tb</italic>PTR1.</p>
        <p>This is exemplified using compound DDD00066641 (6-<italic>p</italic>-tolylquinazoline-2,4-diamine), which was identified as a potent inhibitor of <italic>Tb</italic>PTR1 using the coupled assay, with an average <italic>K</italic><sub>i</sub><sup>app</sup> of 9.8 ± 2.6 nM (<xref rid="fig6" ref-type="fig">Fig. 6</xref>B). For a competitive inhibitor, <italic>K</italic><sub>i</sub> = <italic>K</italic><sub>i</sub><sup>app</sup> (1 + <italic>S</italic>/<italic>K</italic><sub>m</sub>), yielding a <italic>K</italic><sub>i</sub> of 3.0 ± 0.8 nM. The structure of the ternary complex of <italic>Tb</italic>PTR1 with this ligand and the cofactor NADP<sup>+</sup> was obtained by cocrystallization (<xref rid="fig9" ref-type="fig">Fig. 9</xref>A). The binding mode of the ligand is similar to that observed for MTX bound to <italic>Tb</italic>PTR1 <xref rid="bib16" ref-type="bibr">[16]</xref>, with the diaminoquinazoline ring of DDD00066641 sandwiched between the nicotinamide ring of the cofactor and the side chain of Phe97 (<xref rid="fig9" ref-type="fig">Fig. 9</xref>B). The diaminoquinazoline ring of DDD00066641 also shows an identical pattern of H-bond interactions to the protein chain and cofactor, as observed for the pteridine ring of MTX. The ligand forms three H-bonds to the protein: the 2 amino group interacting with both the main chain carbonyl and side chain hydroxyl of Ser95 and the 4 amino group interacting with the side chain hydroxyl of Tyr174. Two H-bonds are also formed via the N1 atom to the α-phosphate group and from the N3 atom to the nicotinamide ribose 2′ hydroxyl. The hydrophobic toluene substituent packs against a hydrophobic surface formed by the side chains of Leu209, Pro210, Met213, and Tyr221.</p>
        <p>The medicinal chemistry program to date has yielded a number of compound series with single digit nanomolar <italic>K</italic><sub>i</sub><sup>app</sup> values for <italic>Tb</italic>PTR1. Furthermore, individual series have been developed with equipotent, <italic>Tb</italic>PTR1-selective, and <italic>Tb</italic>DHFR-TS-selective profiles providing the potential to comprehensively probe the biology of pterin and folate metabolism in the African trypanosome. Routine cocrystallization studies with <italic>Tb</italic>PTR1 across these series have repeatedly confirmed the binding mode revealed for DDD00066641.</p>
      </sec>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>In this article, we have presented the development and validation of a nonenzymatically coupled microtiter plate-based assay for PTR1 and DHFR-TS. The assay was developed to enable a drug discovery project to identify and develop small-molecule inhibitor series of both PTR1 and DHFR-TS in the African trypanosome. The assay platform described in this article was thoroughly validated as an accurate read-out of PTR1 and DHFR-TS activity in vitro through a number of experimental approaches.</p>
      <p>The potency of a known inhibitor, MTX, observed against <italic>Tb</italic>PTR1 using the novel screening assay (IC<sub>50</sub> = 13.7 ± 2.1 nM) was in good agreement with the potencies reported for <italic>L. major</italic> <xref rid="bib10 bib11 bib39" ref-type="bibr">[10,11,39]</xref>, <italic>Leishmania tarentolae</italic> <xref rid="bib39" ref-type="bibr">[39]</xref>, and <italic>Trypanosoma cruzi</italic> <xref rid="bib40" ref-type="bibr">[40]</xref>. Similarly, the IC<sub>50</sub> of MTX observed against <italic>Tb</italic>DHFR-TS using the coupled assay (IC<sub>50</sub> = 0.64 ± 0.28 nM and <italic>K</italic><sub>i</sub> = 0.15 nM) was in agreement with the IC<sub>50</sub> values reported for human, <italic>Escherichia coli,</italic> and <italic>Pneumocystis</italic> <italic>carinii</italic> DHFR-TS enzymes <xref rid="bib41" ref-type="bibr">[41]</xref>. Further validation was provided by comparison of MTX potency in an orthogonal platform for <italic>Tb</italic>PTR1. The HPLC assay for PTR1 yielded an IC<sub>50</sub> of 8.2 ± 0.2 nM, again in excellent agreement with that produced by our screening assay. Calculation of <italic>K</italic><sub>i</sub> values taking into account tight-binding behavior and substrate load of the respective assays produced nearly identical values (4.0 and 3.5 nM for screening and HPLC assays, respectively).</p>
      <p>Analysis and comparison of PTR1 and DHFR-TS substrate <italic>K</italic><sub>m</sub> values between assay platforms revealed some interesting observations. Whereas DHFR-TS enzymes are restricted in their substrate repertoire, primarily reducing H<sub>2</sub>F to H<sub>4</sub>F, PTR1 can reduce numerous pterins and folates. Furthermore, there are substantial interspecies differences in PTR1 activity and substrate sensitivities <xref rid="bib42" ref-type="bibr">[42]</xref>. Substrate inhibition of <italic>Tb</italic>PTR1 in response to H<sub>2</sub>B has also been reported in both <italic>Tb</italic>PTR1 and <italic>Lm</italic>PTR1 <xref rid="bib16" ref-type="bibr">[16]</xref> but has not been reported for DHFR-TS in any species. Consistent with the literature, substrate titrations at a fixed enzyme concentration identified substrate inhibition of <italic>Tb</italic>PTR1 (with H<sub>2</sub>B) but not of <italic>Tb</italic>DHFR-TS. The <italic>K</italic><sub>m</sub><sup>app</sup> for <italic>Tb</italic>DHFR-TS determined in the screening assay agrees well with literature reports <xref rid="bib43 bib44 bib45" ref-type="bibr">[43–45]</xref>.</p>
      <p>The <italic>K</italic><sub>m</sub><sup>app</sup> for <italic>Tb</italic>PTR1 in the screening assay was determined to be 167 ± 54 nM, which is considerably lower than the previously reported <italic>K</italic><sub>m</sub> for <italic>Tb</italic>PTR1 (10.9 ± 2.4 μM) <xref rid="bib16" ref-type="bibr">[16]</xref>. However, the <italic>K</italic><sub>m</sub><sup>app</sup> was determined at pH 6.0 in the current study, not at pH 3.7 as described by Dawson and coworkers <xref rid="bib16" ref-type="bibr">[16]</xref>. To support the determination of <italic>K</italic><sub>m</sub> using the screening assay, <italic>K</italic><sub>m</sub> was also determined using the HPLC assay at pH 6.0. Substrate inhibition with respect to H<sub>2</sub>B was also observed in the HPLC assay, and a nanomolar <italic>K</italic><sub>m</sub><sup>app</sup> was determined (25 ± 6.7 nM). This small shift in apparent affinity for substrate between the screening assay and the HPLC assay is most likely a result of the mixture of biopterin species present in the coupled assay (H<sub>2</sub>B and qH<sub>2</sub>B) that are not present at steady-state levels in the HPLC assay. It is also possible that the mixture of species in the coupled assay contributes significantly to the initial lag phase observed, with qH<sub>2</sub>B possibly being a more efficient substrate for PTR1 than H<sub>2</sub>B itself and linearity being achieved only after a steady state of these species has been attained. In support of this notion, the lag phase is considerably shorter in the equivalent DHFR assay.</p>
      <p>The ultimate validation of the ability of a screening assay to robustly identify inhibitors is in the confirmation of identified actives as genuine binders to the target in question. We have shown, using cocrystallization studies, that an example small molecule identified using the screening assay described here binds to <italic>Tb</italic>PTR1 through interactions within the pterin binding pocket in a manner similar to that observed for MTX. Furthermore, the structure–activity relationships developed and informed by data generated by the screening assay conform well to the binding modes identified for multiple series through similar cocrystallization studies.</p>
      <p>Another key attribute for a screening assay is that it should be deemed as fit for purpose. This screening assay was developed to enable a structure-guided medicinal chemistry project and, therefore, was required to produce accurate reproducible (<italic>n</italic> = 2) potency data for up to three targets (<italic>Tb</italic>PTR1, <italic>Tb</italic>DHFR-TS, and human DHFR) for up to 20 compounds each week for a period of at least 12 months. We have demonstrated in this article that the platform developed was able to consistently produce assay statistics that were highly acceptable in terms of individual plate <italic>Z</italic>′ values and returned potency values for the known inhibitor MTX that were within expectations based on comparison with literature and alternative assay platforms. Furthermore, these key performance metrics were maintained longitudinally over the time period of the project, allowing high levels of plate approval and minimal rescreening. Across a period of 18 months, the project produced approximately 1500 approved concentration–effect curves employing the novel screening assay.</p>
      <p>In summary, we have developed a screening assay that is suitable for routine inhibitor assessment for both PTR1 and DHFR-TS targets. The assay principle relies on H<sub>4</sub>B and H<sub>4</sub>F, the products of catalysis by <italic>Tb</italic>PTR1 and <italic>Tb</italic>DHFR-TS, respectively, reducing cyt <italic>c</italic> and resulting in an increase in signal at 550 nm. Unlike the conventional spectrophotometric absorbance assay measuring oxidation of NADPH at 340 nm, the novel assay provides the throughput, enhanced sensitivity, and extended period of linearity required of an end-point drug discovery screening assay. We believe that the enhanced sensitivity and extended window of linearity are the result of a cycling reaction involving H<sub>4</sub>B, which itself reduces cyt <italic>c</italic> forming qH<sub>2</sub>B and which can subsequently dissociate to H<sub>2</sub>B. The HPLC assay also described in this article will be used to support detailed mode of inhibition studies for key compounds. Full details of enzymatic and biological activities of inhibitors discovered using this assay method will be published separately <xref rid="bib46" ref-type="bibr">[46]</xref>.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>We thank Daniel James for his data management contribution and Petr Kuzmic for his expertise in application of <italic>BatchK<sub>i</sub></italic> software to this project. This work was supported by the Wellcome Trust (WT 077705, WT 079838, and WT 083481).</p>
    </ack>
    <fn-group>
      <fn id="fn1">
        <label>1</label>
        <p><italic>Abbreviations used:</italic> HAT, human African trypanosomiasis; H<sub>4</sub>B, 5,6,7,8-tetrahydrobiopterin; H<sub>4</sub>F, 5,6,7,8-tetrahydrofolate; PTR1, pteridine reductase 1; NADPH, nicotinamide adenine dinucleotide phosphate; DHFR-TS, dihydrofolate reductase–thymidylate synthase; SHMT, serine hydroxymethyltransferase; dTMP, thymidylate; H<sub>2</sub>F, dihydrofolate; B, biopterin; H<sub>2</sub>B, 7,8-dihydrobiopterin; DMPK, drug metabolism and pharmacokinetics; <italic>Tb</italic>DHFR-TS, <italic>T. brucei</italic> DHFR-TS; <italic>Tb</italic>PTR1, <italic>T. brucei</italic> PTR1; HPLC, high-performance liquid chromatography; cyt <italic>c,</italic> cytochrome <italic>c</italic>; PCR, polymerase chain reaction; GST, glutathione <italic>S</italic>-transferase; GSH, glutathione; MTX, methotrexate; EDTA, ethylenediaminetetraacetic acid; DMSO, dimethyl sulfoxide; PTB, Protein Data Bank; cyt <italic>c</italic> Fe<sup>3+</sup>, ferricytochrome <italic>c</italic>; qH<sub>2</sub>B, quinonoid H<sub>2</sub>B; UV–Vis, ultraviolet–visible.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="bib1">
        <label>[1]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stuart</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Brun</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Croft</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Fairlamb</surname>
              <given-names>A.H.</given-names>
            </name>
            <name>
              <surname>Gurtler</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>McKerrow</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Reed</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tarleton</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Kinetoplastids: related protozoan pathogens, different diseases</article-title>
          <source>J. Clin. Invest.</source>
          <year>2008</year>
          <volume>118</volume>
          <fpage>1301</fpage>
          <lpage>1310</lpage>
          <pub-id pub-id-type="pmid">18382742</pub-id>
        </citation>
      </ref>
      <ref id="bib2">
        <label>[2]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trouiller</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Olliaro</surname>
              <given-names>P.L.</given-names>
            </name>
          </person-group>
          <article-title>Drug development output from 1975 to 1996: what proportion for tropical diseases?</article-title>
          <source>Intl. J. Infect. Dis.</source>
          <year>1999</year>
          <volume>3</volume>
          <fpage>61</fpage>
          <lpage>63</lpage>
        </citation>
      </ref>
      <ref id="bib3">
        <label>[3]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nare</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Luba</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Hardy</surname>
              <given-names>L.W.</given-names>
            </name>
            <name>
              <surname>Beverley</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>New approaches to Leishmania chemotherapy: Pteridine reductase 1 (PTR1) as a target and modulator of antifolate sensitivity</article-title>
          <source>Parasitology</source>
          <year>1997</year>
          <volume>114</volume>
          <fpage>101</fpage>
          <lpage>110</lpage>
        </citation>
      </ref>
      <ref id="bib4">
        <label>[4]</label>
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Ouellette</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Papadopoulou</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Haimeur</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Grondin</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Leblanc</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Légaré</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Roy</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Transport of antifolates and antimonials in drug-resistant Leishmania</article-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Georgopapadakou</surname>
              <given-names>N.H.</given-names>
            </name>
          </person-group>
          <source>Drug Transport in Antimicrobial and Anticancer Chemotherapy</source>
          <year>1995</year>
          <publisher-name>Marcel Decker</publisher-name>
          <publisher-loc>New York</publisher-loc>
          <fpage>377</fpage>
          <lpage>402</lpage>
        </citation>
      </ref>
      <ref id="bib5">
        <label>[5]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berriman</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ghedin</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Hertz-Fowler</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Blandin</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Renauld</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Bartholomeu</surname>
              <given-names>D.C.</given-names>
            </name>
            <name>
              <surname>Lennard</surname>
              <given-names>N.J.</given-names>
            </name>
            <name>
              <surname>Caler</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Hamlin</surname>
              <given-names>N.E.</given-names>
            </name>
            <name>
              <surname>Haas</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>The genome of the African trypanosome Trypanosoma brucei</article-title>
          <source>Science</source>
          <year>2005</year>
          <volume>309</volume>
          <fpage>416</fpage>
          <lpage>422</lpage>
          <pub-id pub-id-type="pmid">16020726</pub-id>
        </citation>
      </ref>
      <ref id="bib6">
        <label>[6]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scott</surname>
              <given-names>D.A.</given-names>
            </name>
            <name>
              <surname>Hickerson</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Vickers</surname>
              <given-names>T.J.</given-names>
            </name>
            <name>
              <surname>Beverley</surname>
              <given-names>S.M.</given-names>
            </name>
          </person-group>
          <article-title>The role of the mitochondrial glycine cleavage complex in the metabolism and virulence of the protozoan parasite Leishmania major</article-title>
          <source>J. Biol. Chem.</source>
          <year>2008</year>
          <volume>283</volume>
          <fpage>155</fpage>
          <lpage>165</lpage>
          <pub-id pub-id-type="pmid">17981801</pub-id>
        </citation>
      </ref>
      <ref id="bib7">
        <label>[7]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cruz</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Coburn</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Beverley</surname>
              <given-names>S.M.</given-names>
            </name>
          </person-group>
          <article-title>Double targeted gene replacement for creating null mutants</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <year>1991</year>
          <volume>88</volume>
          <fpage>7170</fpage>
          <lpage>7174</lpage>
          <pub-id pub-id-type="pmid">1651496</pub-id>
        </citation>
      </ref>
      <ref id="bib8">
        <label>[8]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sienkiewicz</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Jaroslawski</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Wyllie</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Fairlamb</surname>
              <given-names>A.H.</given-names>
            </name>
          </person-group>
          <article-title>Chemical and genetic validation of dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes</article-title>
          <source>Mol. Microbiol.</source>
          <year>2008</year>
          <volume>69</volume>
          <fpage>520</fpage>
          <lpage>533</lpage>
          <pub-id pub-id-type="pmid">18557814</pub-id>
        </citation>
      </ref>
      <ref id="bib9">
        <label>[9]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amaral</surname>
              <given-names>V.F.</given-names>
            </name>
            <name>
              <surname>Teva</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Oliveira-Neto</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Cupolillo</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Porrozzi</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Coutinho</surname>
              <given-names>S.G.</given-names>
            </name>
            <name>
              <surname>Pirmez</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Beverley</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Grimaldi</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Study of the safety, immunogenicity, and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease</article-title>
          <source>Mem. Inst. Oswaldo Cruz</source>
          <year>2002</year>
          <volume>97</volume>
          <fpage>1041</fpage>
          <lpage>1048</lpage>
          <pub-id pub-id-type="pmid">12471434</pub-id>
        </citation>
      </ref>
      <ref id="bib10">
        <label>[10]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bello</surname>
              <given-names>A.R.</given-names>
            </name>
            <name>
              <surname>Nare</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Freedman</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hardy</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Beverley</surname>
              <given-names>S.M.</given-names>
            </name>
          </person-group>
          <article-title>PTR1: a reductase mediating salvage of oxidized pteridines and methotrexate resistance in the protozoan parasite Leishmania major</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <year>1994</year>
          <volume>91</volume>
          <fpage>11442</fpage>
          <lpage>11446</lpage>
          <pub-id pub-id-type="pmid">7972081</pub-id>
        </citation>
      </ref>
      <ref id="bib11">
        <label>[11]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nare</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Hardy</surname>
              <given-names>L.W.</given-names>
            </name>
            <name>
              <surname>Beverley</surname>
              <given-names>S.M.</given-names>
            </name>
          </person-group>
          <article-title>The roles of pteridine reductase 1 and dihydrofolate reductase-thymidylate synthase in pteridine metabolism in the protozoan parasite Leishmania major</article-title>
          <source>J. Biol. Chem.</source>
          <year>1997</year>
          <volume>272</volume>
          <fpage>13883</fpage>
          <lpage>13891</lpage>
          <pub-id pub-id-type="pmid">9153248</pub-id>
        </citation>
      </ref>
      <ref id="bib12">
        <label>[12]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>D.Q.</given-names>
            </name>
            <name>
              <surname>Beverley</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Turco</surname>
              <given-names>S.J.</given-names>
            </name>
          </person-group>
          <article-title>Leishmania donovani possess a NADPH-dependent alkylglycerol cleavage enzyme</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <year>1996</year>
          <volume>227</volume>
          <fpage>885</fpage>
          <lpage>889</lpage>
          <pub-id pub-id-type="pmid">8886025</pub-id>
        </citation>
      </ref>
      <ref id="bib13">
        <label>[13]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ouellette</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Drummelsmith</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>El Fadili</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kundig</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Richard</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Roy</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Pterin transport and metabolism in Leishmania and related trypanosomatid parasites</article-title>
          <source>Intl. J. Parasitol.</source>
          <year>2002</year>
          <volume>32</volume>
          <fpage>385</fpage>
          <lpage>398</lpage>
        </citation>
      </ref>
      <ref id="bib14">
        <label>[14]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cunningham</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Titus</surname>
              <given-names>R.G.</given-names>
            </name>
            <name>
              <surname>Turco</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Beverley</surname>
              <given-names>S.M.</given-names>
            </name>
          </person-group>
          <article-title>Regulation of differentiation to the infective stage of the protozoan parasite Leishmania major by tetrahydrobiopterin</article-title>
          <source>Science</source>
          <year>2001</year>
          <volume>292</volume>
          <fpage>285</fpage>
          <lpage>287</lpage>
          <pub-id pub-id-type="pmid">11303103</pub-id>
        </citation>
      </ref>
      <ref id="bib15">
        <label>[15]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frearson</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Wyatt</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Gilbert</surname>
              <given-names>I.H.</given-names>
            </name>
            <name>
              <surname>Fairlamb</surname>
              <given-names>A.H.</given-names>
            </name>
          </person-group>
          <article-title>Target assessment for antiparasitic drug discovery</article-title>
          <source>Trends Parasitol.</source>
          <year>2007</year>
          <volume>23</volume>
          <fpage>589</fpage>
          <lpage>595</lpage>
          <pub-id pub-id-type="pmid">17962072</pub-id>
        </citation>
      </ref>
      <ref id="bib16">
        <label>[16]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dawson</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Gibellini</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Sienkiewicz</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Tulloch</surname>
              <given-names>L.B.</given-names>
            </name>
            <name>
              <surname>Fyfe</surname>
              <given-names>P.K.</given-names>
            </name>
            <name>
              <surname>McLuskey</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Fairlamb</surname>
              <given-names>A.H.</given-names>
            </name>
            <name>
              <surname>Hunter</surname>
              <given-names>W.N.</given-names>
            </name>
          </person-group>
          <article-title>Structure and reactivity of Trypanosoma brucei pteridine reductase: Inhibition by the archetypal antifolate methotrexate</article-title>
          <source>Mol. Microbiol.</source>
          <year>2006</year>
          <volume>61</volume>
          <fpage>1457</fpage>
          <lpage>1468</lpage>
          <pub-id pub-id-type="pmid">16968221</pub-id>
        </citation>
      </ref>
      <ref id="bib17">
        <label>[17]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bradford</surname>
              <given-names>M.M.</given-names>
            </name>
          </person-group>
          <article-title>A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding</article-title>
          <source>Anal. Biochem.</source>
          <year>1976</year>
          <volume>72</volume>
          <fpage>248</fpage>
          <lpage>254</lpage>
          <pub-id pub-id-type="pmid">942051</pub-id>
        </citation>
      </ref>
      <ref id="bib18">
        <label>[18]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cunningham</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Beverley</surname>
              <given-names>S.M.</given-names>
            </name>
          </person-group>
          <article-title>Pteridine salvage throughout the Leishmania infectious cycle: Implications for antifolate chemotherapy</article-title>
          <source>Mol. Biochem. Parasitol.</source>
          <year>2001</year>
          <volume>113</volume>
          <fpage>199</fpage>
          <lpage>213</lpage>
          <pub-id pub-id-type="pmid">11295174</pub-id>
        </citation>
      </ref>
      <ref id="bib19">
        <label>[19]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fukushima</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Nixon</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <article-title>Analysis of reduced forms of biopterin in biological tissues and fluids</article-title>
          <source>Anal. Biochem.</source>
          <year>1980</year>
          <volume>102</volume>
          <fpage>176</fpage>
          <lpage>188</lpage>
          <pub-id pub-id-type="pmid">7356152</pub-id>
        </citation>
      </ref>
      <ref id="bib20">
        <label>[20]</label>
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Pfleiderer</surname>
              <given-names>W.</given-names>
            </name>
          </person-group>
          <article-title>Chemistry of naturally occurring pterins</article-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Blakeley</surname>
              <given-names>R.L.</given-names>
            </name>
            <name>
              <surname>Benkovic</surname>
              <given-names>S.J.</given-names>
            </name>
          </person-group>
          <source>Chemistry and Biochemistry of Pterins</source>
          <year>1985</year>
          <publisher-name>John Wiley</publisher-name>
          <publisher-loc>New York</publisher-loc>
          <fpage>43</fpage>
          <lpage>114</lpage>
        </citation>
      </ref>
      <ref id="bib21">
        <label>[21]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leslie</surname>
              <given-names>A.G.W.</given-names>
            </name>
          </person-group>
          <article-title>Recent changes to the MOSFLM package for processing film and image plate data, Joint CCP4+ESF−EAMCB</article-title>
          <source>Newslett. Protein Crystallogr.</source>
          <year>1992</year>
          <volume>26</volume>
          <fpage>1</fpage>
          <lpage>10</lpage>
        </citation>
      </ref>
      <ref id="bib22">
        <label>[22]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Evans</surname>
              <given-names>P.R.</given-names>
            </name>
          </person-group>
          <article-title>SCALA, Joint CCP4+ESF−EAMCB</article-title>
          <source>Newslett. Protein Crystallogr.</source>
          <year>1997</year>
          <volume>33</volume>
          <fpage>22</fpage>
          <lpage>24</lpage>
        </citation>
      </ref>
      <ref id="bib23">
        <label>[23]</label>
        <citation citation-type="other">Collaborative Computational Project no. 4, The CCP4 suite: programs for protein crystallography, Acta Crystallogr. D 50 (1994) 760–763.</citation>
      </ref>
      <ref id="bib24">
        <label>[24]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vagin</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Teplyakov</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>An approach to multi-copy search in molecular replacement</article-title>
          <source>Acta Crystallogr. D</source>
          <year>2000</year>
          <volume>56</volume>
          <fpage>1622</fpage>
          <lpage>1624</lpage>
          <pub-id pub-id-type="pmid">11092928</pub-id>
        </citation>
      </ref>
      <ref id="bib25">
        <label>[25]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murshudov</surname>
              <given-names>G.N.</given-names>
            </name>
            <name>
              <surname>Vagin</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Dodson</surname>
              <given-names>E.J.</given-names>
            </name>
          </person-group>
          <article-title>Refinement of macromolecular structures by the maximum-likelihood method</article-title>
          <source>Acta Crystallogr. D</source>
          <year>1997</year>
          <volume>53</volume>
          <fpage>240</fpage>
          <lpage>255</lpage>
          <pub-id pub-id-type="pmid">15299926</pub-id>
        </citation>
      </ref>
      <ref id="bib26">
        <label>[26]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schuttelkopf</surname>
              <given-names>A.W.</given-names>
            </name>
            <name>
              <surname>van Aalten</surname>
              <given-names>D.M.</given-names>
            </name>
          </person-group>
          <article-title>PRODRG: a tool for high-throughput crystallography of protein–ligand complexes</article-title>
          <source>Acta Crystallogr. D</source>
          <year>2004</year>
          <volume>60</volume>
          <fpage>1355</fpage>
          <lpage>1363</lpage>
          <pub-id pub-id-type="pmid">15272157</pub-id>
        </citation>
      </ref>
      <ref id="bib27">
        <label>[27]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Emsley</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Cowtan</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>COOT: model-building tools for molecular graphics</article-title>
          <source>Acta Crystallogr. D</source>
          <year>2004</year>
          <volume>60</volume>
          <fpage>2126</fpage>
          <lpage>2132</lpage>
          <pub-id pub-id-type="pmid">15572765</pub-id>
        </citation>
      </ref>
      <ref id="bib28">
        <label>[28]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morrison</surname>
              <given-names>J.F.</given-names>
            </name>
          </person-group>
          <article-title>Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors</article-title>
          <source>Biochem. Biophys. Acta</source>
          <year>1969</year>
          <volume>185</volume>
          <fpage>269</fpage>
          <lpage>286</lpage>
          <pub-id pub-id-type="pmid">4980133</pub-id>
        </citation>
      </ref>
      <ref id="bib29">
        <label>[29]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Williams</surname>
              <given-names>J.W.</given-names>
            </name>
            <name>
              <surname>Morrison</surname>
              <given-names>J.F.</given-names>
            </name>
          </person-group>
          <article-title>The kinetics of reversible tight-binding inhibition</article-title>
          <source>Methods Enzymol.</source>
          <year>1979</year>
          <volume>63</volume>
          <fpage>437</fpage>
          <lpage>467</lpage>
          <pub-id pub-id-type="pmid">502865</pub-id>
        </citation>
      </ref>
      <ref id="bib30">
        <label>[30]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuzmic</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Sideris</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Cregar</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Elrod</surname>
              <given-names>K.C.</given-names>
            </name>
            <name>
              <surname>Rice</surname>
              <given-names>K.D.</given-names>
            </name>
            <name>
              <surname>Janc</surname>
              <given-names>J.W.</given-names>
            </name>
          </person-group>
          <article-title>High-throughput screening of enzyme inhibitors: automatic determination of tight-binding inhibition constants</article-title>
          <source>Anal. Biochem.</source>
          <year>2000</year>
          <volume>281</volume>
          <fpage>62</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="pmid">10847611</pub-id>
        </citation>
      </ref>
      <ref id="bib31">
        <label>[31]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuzmic</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Elrod</surname>
              <given-names>K.C.</given-names>
            </name>
            <name>
              <surname>Cregar</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Sideris</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rai</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Janc</surname>
              <given-names>J.W.</given-names>
            </name>
          </person-group>
          <article-title>High-throughput enzyme kinetics: Simultaneous determination of tight-binding inhibition constants and enzyme concentration</article-title>
          <source>Anal. Biochem.</source>
          <year>2000</year>
          <volume>286</volume>
          <fpage>45</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="pmid">11038272</pub-id>
        </citation>
      </ref>
      <ref id="bib32">
        <label>[32]</label>
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Reich</surname>
              <given-names>J.-G.</given-names>
            </name>
          </person-group>
          <article-title>Curve Fitting and Modeling for Scientists and Engineers</article-title>
          <year>1992</year>
          <publisher-name>McGraw-Hill</publisher-name>
          <publisher-loc>New York</publisher-loc>
        </citation>
      </ref>
      <ref id="bib33">
        <label>[33]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marquardt</surname>
              <given-names>D.W.</given-names>
            </name>
          </person-group>
          <article-title>An algorithm for least-squares estimation of nonlinear parameters</article-title>
          <source>J. Soc. Ind. Appl. Math.</source>
          <year>1963</year>
          <volume>11</volume>
          <fpage>431</fpage>
          <lpage>441</lpage>
        </citation>
      </ref>
      <ref id="bib34">
        <label>[34]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuzmic</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Practical robust fit of enzyme inhibition data</article-title>
          <source>Methods Enzymol.</source>
          <year>2004</year>
          <volume>383</volume>
          <fpage>366</fpage>
          <lpage>381</lpage>
          <pub-id pub-id-type="pmid">15063658</pub-id>
        </citation>
      </ref>
      <ref id="bib35">
        <label>[35]</label>
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Huber</surname>
              <given-names>P.J.</given-names>
            </name>
          </person-group>
          <article-title>Robust Statistics</article-title>
          <year>1981</year>
          <publisher-name>John Wiley</publisher-name>
          <publisher-loc>New York</publisher-loc>
        </citation>
      </ref>
      <ref id="bib36">
        <label>[36]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>J.-H.</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>T.D.Y.</given-names>
            </name>
            <name>
              <surname>Oldenburg</surname>
              <given-names>K.R.</given-names>
            </name>
          </person-group>
          <article-title>A simple statistical parameter for use in evaluation and validation of high throughput screening assays</article-title>
          <source>J. Biomol. Screen.</source>
          <year>1999</year>
          <volume>4</volume>
          <fpage>67</fpage>
          <lpage>73</lpage>
          <pub-id pub-id-type="pmid">10838414</pub-id>
        </citation>
      </ref>
      <ref id="bib37">
        <label>[37]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hasegawa</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Nakanishi</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Akino</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Stoichiometric studies on the oxidation of tetrahydropterin with ferri-cytochrome c</article-title>
          <source>J. Biochem. (Tokyo)</source>
          <year>1978</year>
          <volume>84</volume>
          <fpage>499</fpage>
          <lpage>506</lpage>
          <pub-id pub-id-type="pmid">214425</pub-id>
        </citation>
      </ref>
      <ref id="bib38">
        <label>[38]</label>
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Copeland</surname>
              <given-names>R.A.</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists</article-title>
          <year>2005</year>
          <publisher-name>Wiley Interscience</publisher-name>
          <publisher-loc>New York</publisher-loc>
        </citation>
      </ref>
      <ref id="bib39">
        <label>[39]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chang</surname>
              <given-names>C.-F.</given-names>
            </name>
            <name>
              <surname>Bray</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Whiteley</surname>
              <given-names>J.M.</given-names>
            </name>
          </person-group>
          <article-title>Mutant PTR1 proteins from Leishmania tarentolae: Comparative kinetic properties and active-site labeling</article-title>
          <source>Arch. Biochem. Biophys.</source>
          <year>1999</year>
          <volume>368</volume>
          <fpage>161</fpage>
          <lpage>171</lpage>
          <pub-id pub-id-type="pmid">10415124</pub-id>
        </citation>
      </ref>
      <ref id="bib40">
        <label>[40]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schormann</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Pal</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Senkovich</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Carson</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Howard</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>DeLucas</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Chattopadhyay</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of Trypanosoma cruzi pteridine reductase 2 in complex with a substrate and an inhibitor</article-title>
          <source>J. Struct. Biol.</source>
          <year>2005</year>
          <volume>152</volume>
          <fpage>64</fpage>
          <lpage>75</lpage>
          <pub-id pub-id-type="pmid">16168672</pub-id>
        </citation>
      </ref>
      <ref id="bib41">
        <label>[41]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Edman</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Edman</surname>
              <given-names>U.</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lundgren</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Kovacs</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Santi</surname>
              <given-names>D.V.</given-names>
            </name>
          </person-group>
          <article-title>Isolation and expression of the Pneumocystis carinii dihydrofolate reductase gene</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <year>1989</year>
          <volume>86</volume>
          <fpage>8625</fpage>
          <lpage>8629</lpage>
          <pub-id pub-id-type="pmid">2682653</pub-id>
        </citation>
      </ref>
      <ref id="bib42">
        <label>[42]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robello</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Navarro</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Castanys</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Gamarro</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>A pteridine reductase gene ptr1 contiguous to a P-glycoprotein confers resistance to antifolates in Trypanosoma cruzi</article-title>
          <source>Mol. Biochem. Parasitol.</source>
          <year>1997</year>
          <volume>90</volume>
          <fpage>525</fpage>
          <lpage>535</lpage>
          <pub-id pub-id-type="pmid">9476799</pub-id>
        </citation>
      </ref>
      <ref id="bib43">
        <label>[43]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arrebola</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Olmo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Reche</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Garvey</surname>
              <given-names>E.P.</given-names>
            </name>
            <name>
              <surname>Santi</surname>
              <given-names>D.V.</given-names>
            </name>
            <name>
              <surname>Ruiz-Perez</surname>
              <given-names>L.M.</given-names>
            </name>
            <name>
              <surname>Gonzalez-Pacanowska</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Isolation and characterization of a mutant dihydrofolate reductase–thymidylate synthase from methotrexate-resistant Leishmania cells</article-title>
          <source>J. Biol. Chem.</source>
          <year>1994</year>
          <volume>269</volume>
          <fpage>10590</fpage>
          <lpage>10596</lpage>
          <pub-id pub-id-type="pmid">8144647</pub-id>
        </citation>
      </ref>
      <ref id="bib44">
        <label>[44]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trujillo</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Duncan</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Santi</surname>
              <given-names>D.V.</given-names>
            </name>
          </person-group>
          <article-title>Construction of a homodimeric dihydrofolate reductase–thymidylate synthase bifunctional enzyme</article-title>
          <source>Prot. Eng.</source>
          <year>1997</year>
          <volume>10</volume>
          <fpage>567</fpage>
          <lpage>573</lpage>
        </citation>
      </ref>
      <ref id="bib45">
        <label>[45]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jaffe</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>McCormack</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Gutteridge</surname>
              <given-names>W.E.</given-names>
            </name>
          </person-group>
          <article-title>Dihydrofolate reductases with the genus Trypanosoma</article-title>
          <source>Exp. Parasitol.</source>
          <year>1969</year>
          <volume>25</volume>
          <fpage>311</fpage>
          <lpage>318</lpage>
          <pub-id pub-id-type="pmid">5362591</pub-id>
        </citation>
      </ref>
      <ref id="bib46">
        <label>[46]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mpamhanga</surname>
              <given-names>C.P.</given-names>
            </name>
            <name>
              <surname>Spinks</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Tulloch</surname>
              <given-names>L.B.</given-names>
            </name>
            <name>
              <surname>Shanks</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Collie</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Fairlamb</surname>
              <given-names>A.H.</given-names>
            </name>
            <name>
              <surname>Wyatt</surname>
              <given-names>P.W.</given-names>
            </name>
            <name>
              <surname>Frearson</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Hunter</surname>
              <given-names>W.N.</given-names>
            </name>
            <name>
              <surname>Gilbert</surname>
              <given-names>I.H.</given-names>
            </name>
            <name>
              <surname>Brenk</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>One scaffold, three binding modes: Novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening</article-title>
          <source>J. Med. Chem.</source>
          <year>2009</year>
          <volume>52</volume>
          <fpage>4454</fpage>
          <lpage>4465</lpage>
          <pub-id pub-id-type="pmid">19527033</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
  <floats-wrap>
    <fig id="fig1">
      <label>Fig. 1</label>
      <caption>
        <p>Principle of the cyt <italic>c</italic>-coupled assay for <italic>Tb</italic>PTR1. H<sub>2</sub>B is reduced by NADPH (ε<sub>340nm</sub> = 6.22 mM<sup>−1</sup> cm<sup>−1</sup>) and <italic>Tb</italic>PTR1 to H<sub>4</sub>B, which then nonenzymatically reduces cyt <italic>c</italic> Fe<sup>3+</sup> to cyt <italic>c</italic> Fe<sup>2+</sup> (Δε<sub>550nm</sub> = 21.1 mM<sup>−1</sup> cm<sup>−1</sup>) and qH<sub>2</sub>B <xref rid="bib20" ref-type="bibr">[20]</xref>. Under anaerobic conditions, the stoichiometry is 2 mol cytochrome <italic>c</italic>/mol NADPH and 1.5- to 1.8-fold under aerobic conditions <xref rid="bib19" ref-type="bibr">[19]</xref>, leading to an increase in absorbance signal of 5- to 6-fold. qH<sub>2</sub>B is unstable at near neutral pH and spontaneously isomerizes principally to H<sub>2</sub>B <xref rid="bib20" ref-type="bibr">[20]</xref>.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="fig2">
      <label>Fig. 2</label>
      <caption>
        <p>Optimization of the cyt <italic>c</italic>-coupled assay for <italic>Tb</italic>PTR1. (A) Reduction of cyt <italic>c</italic> by <italic>Tb</italic>PTR1 activity. The absorbance spectrum of cyt <italic>c</italic> (80 μM) was measured at intervals (20, 40, and 60 min) in the presence of <italic>Tb</italic>PTR1 (20 nM), H<sub>2</sub>B (0.5 μM), and NADPH (100 μM) using a cuvette-based assay. Controls omitting one of the components give identical spectra to the zero time trace (not shown). Na<sup>+</sup> dithionite was added to completely reduce residual cyt <italic>c.</italic> (B) Determination of optimum pH. Assays contained 4.8 nM <italic>Tb</italic>PTR1, 0.35 μM H<sub>2</sub>B, 80 μM cyt <italic>c</italic>, and 100 μM NADPH in a range of buffers—Na<sup>+</sup> citrate (closed circles), Na<sup>+</sup> phosphate (open squares), and Tris (closed squares) (all at 20 mM)—containing 1 mM EDTA adjusted to different pH values with citric acid, phosphoric acid, and Na<sup>+</sup> hydroxide, respectively. Absorbance at 550 nm was measured after 60 min. (C) Determination of optimum cyt <italic>c</italic> concentration. Assays contained 4.8 nM <italic>Tb</italic>PTR1, 0.35 μM H<sub>2</sub>B, and 100 μM NADPH in 20 mM Na<sup>+</sup> citrate/1 mM EDTA buffer (pH 6.0) with varying cyt <italic>c</italic> concentrations. Absorbance at 550 nm was measured after 60 min. (D) Proportionality of activity with enzyme concentration. Assays contained varying concentrations of <italic>Tb</italic>PTR1, 0.35 μM H<sub>2</sub>B, 80 μM cyt <italic>c,</italic> and 100 μM NADPH in 20 mM Na<sup>+</sup> citrate/1 mM EDTA buffer (pH 6.0). Absorbance at 550 nm was measured after 60 min. mAbs, monoclonal antibodies. Each data point shown is the mean ± standard deviation of triplicate determinations.</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
    <fig id="fig3">
      <label>Fig. 3</label>
      <caption>
        <p>Time-based linearity of cyt <italic>c</italic>-coupled assay for <italic>Tb</italic>PTR1. Using final assay conditions described in Materials and Methods, signal generation was measured across a time course. Open symbols: plus enzyme (4.8 nM); closed symbols: minus enzyme. The dotted line is the linear regression of the change in absorbance at 550 nm from 20 to 50 min. Data shown are from a representative experiment that was reproduced on three independent occasions. Each data point shown is the mean ± standard deviation of 16 replicates.</p>
      </caption>
      <graphic xlink:href="gr3"/>
    </fig>
    <fig id="fig4">
      <label>Fig. 4</label>
      <caption>
        <p>Determination of <italic>K</italic><sub>m</sub><sup>app</sup> for H<sub>2</sub>B using the coupled assay. (A) Enzyme rate versus substrate concentration. The curve represents the best nonlinear fit to the general equation for substrate inhibition. (B) Lineweaver–Burk transformation of data. The resulting kinetic parameters were as follows: <italic>K</italic><sub>m</sub> = 167 ± 54 nM, <italic>K</italic><sub>i</sub><sup>s</sup> = 439 ± 135 nM, <italic>V</italic><sub>max</sub> = 0.51 ± 0.10 pmol min<sup>−1</sup>, and <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>m</sub> = 5.6 × 10<sup>5</sup> M<sup>−1</sup> s<sup>−1</sup>. Data shown are from a representative experiment that was reproduced on three independent occasions. Each data point shown is the mean of duplicate determinations.</p>
      </caption>
      <graphic xlink:href="gr4"/>
    </fig>
    <fig id="fig5">
      <label>Fig. 5</label>
      <caption>
        <p><italic>Tb</italic>PTR1 assay by HPLC. All assays were carried out in 20 mM citrate, 1 mM EDTA, and 50 μM NADPH (pH 6.0) with specified concentrations of H<sub>2</sub>B and initiated with <italic>Tb</italic>PTR1. Formation of H<sub>4</sub>B product was determined by HPLC as described in Materials and Methods. (A) Linearity of assay at high and low substrate concentrations. Assays contained 1.1 nM <italic>Tb</italic>PTR1, and reactions were terminated at the specified time intervals. Open circles: 10 nM; closed circles: 500 nM H<sub>2</sub>B. (B) Proportionality of activity with enzyme concentration. Assays contained 25 nM H<sub>2</sub>B, and reactions were terminated after 1 min. (C) Enzyme rate versus substrate concentration. Assays contained 1.1 nM <italic>Tb</italic>PTR1, and reactions were terminated after 1 min. The curve represents the best nonlinear fit to the high substrate inhibition equation. (D) Lineweaver–Burk transformation of kinetic data. The resulting kinetic parameters were as follows: <italic>K</italic><sub>m</sub> = 25.0 ± 6.7 nM, <italic>K</italic><sub>i</sub><sup>s</sup> = 37.2 ± 10.4 nM, <italic>V</italic><sub>max</sub> = 4.7 ± 0.9 pmol min<sup>−1</sup>, and <italic>k</italic><sub>cat</sub>/<italic>K</italic><sub>m</sub> = 2.8 × 10<sup>6</sup> M<sup>−1</sup> s<sup>−1</sup>. Data points represent the means and standard deviations of triplicate measurements. Data shown are from representative experiments that were reproduced on three independent occasions. Each data point shown is the mean of triplicate determinations.</p>
      </caption>
      <graphic xlink:href="gr5"/>
    </fig>
    <fig id="fig6">
      <label>Fig. 6</label>
      <caption>
        <p>Inhibition of <italic>Tb</italic>PTR1 by MTX and DDD00066641. (A) Concentration-dependent inhibition by MTX. MTX potency was determined using the cyt <italic>c</italic>-coupled assay (open circles, <italic>n</italic> = 16) and the HPLC assay (closed circles, <italic>n</italic> = 3). For the coupled assay, the mean IC<sub>50</sub> was 13.7 ± 2.1 nM and the Hill slope was 1.19 ± 0.14. The corresponding <italic>K</italic><sub>i</sub><sup>app</sup> was 11.1 ± 2.1 nM. For the HPLC assay, the corresponding values were IC<sub>50</sub> = 8.22 ± 0.21 nM, Hill slope = 2.1 ± 0.1, and <italic>K</italic><sub>i</sub><sup>app</sup> = 7.1 ± 1.0 nM. (B) Concentration-dependent inhibition by DDD00066641 as determined using the cyt <italic>c</italic> method. The IC<sub>50</sub> value was 10.6 nM, the Hill slope was 0.98, and the corresponding <italic>K</italic><sub>i</sub><sup>app</sup> was 9.8 ± 2.6 nM.</p>
      </caption>
      <graphic xlink:href="gr6"/>
    </fig>
    <fig id="fig7">
      <label>Fig. 7</label>
      <caption>
        <p>Summary of <italic>Tb</italic>DHFR-TS assay development for the cyt <italic>c</italic>-coupled assay method. (A) Proportionality of <italic>Tb</italic>DHFR-TS activity with enzyme concentration. (B) Enzyme rate versus substrate concentration. (C) Lineweaver–Burk transformation of data. (D) IC<sub>50</sub> for MTX. The average MTX IC<sub>50</sub> (<italic>n</italic> = 16) against <italic>Tb</italic>DHFR-TS was 0.64 nM ± 0.28 nM, and the Hill slope was 0.78 ± 0.08. The corresponding <italic>K</italic><sub>i</sub><sup>app</sup> was 0.24 ± 0.14 nM. mAbs, monoclonal antibodies. Data shown are from representative experiments that were reproduced on three independent occasions. Each data point shown is the mean of duplicate determinations from two independent experiments.</p>
      </caption>
      <graphic xlink:href="gr7"/>
    </fig>
    <fig id="fig8">
      <label>Fig. 8</label>
      <caption>
        <p>Longitudinal performance monitoring of the novel screening assay. Concentration-dependent inhibition was determined for all compounds screened against <italic>Tb</italic>PTR1 and <italic>Tb</italic>DHFR-TS. Briefly, serial dilution curves (10-point curves, 1:3 dilutions in DMSO) were created and assayed in duplicate using the cyt <italic>c</italic>-coupled assay. All assays were performed as described in Materials and Methods. The correlation between replicate p<italic>K</italic><sub>i</sub><sup>app</sup> (−log <italic>K</italic><sub>i</sub><sup>app</sup>) values is shown for <italic>Tb</italic>PTR1 (A) (<italic>n</italic> = 137 compounds) and <italic>Tb</italic>DHFR-TS (B) (<italic>n</italic> = 80 compounds). (C) Performance of the cyt <italic>c</italic>-coupled assay across a period of 18 months. Closed circles: <italic>Z</italic>′ values; open circles: MTX p<italic>K</italic><sub>i</sub><sup>app</sup> values from all assay plates.</p>
      </caption>
      <graphic xlink:href="gr8"/>
    </fig>
    <fig id="fig9">
      <label>Fig. 9</label>
      <caption>
        <p>Cocrystallization of key compounds with <italic>Tb</italic>PTR1: Detailed views of the <italic>Tb</italic>PTR1 active site in complex with NADPH and DDD00066641. (A) Binding mode of DDD00066641 (green carbon atoms) and the cofactor NADPH (cyan carbon atoms) in the active site (gray carbon atoms). Omit electron density, calculated after one round of refinement with the ligand atoms removed from the model, is shown as green mesh, contoured at 3 sigma. Key residues are labeled for clarity. (B) Binding mode of DDD00066641 (green carbon atoms) superimposed on the binding mode of MTX (pink C atoms). Hydrogen bonds between the ligand and the protein/cofactor are shown as dashed lines, and key residues are labeled for clarity. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</p>
      </caption>
      <graphic xlink:href="gr9"/>
    </fig>
    <table-wrap position="float" id="tbl1">
      <label>Table 1</label>
      <caption>
        <p>Statistical analysis of plate data.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th/>
            <th><italic>Tb</italic>PTR1</th>
            <th><italic>Tb</italic>DHFR-TS</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td>High signal (absorbance units)</td>
            <td align="char">0.44 ± 0.02</td>
            <td align="char">0.43 ± 0.02</td>
          </tr>
          <tr>
            <td>Low signal (absorbance units)</td>
            <td align="char">0.32 ± 0.01</td>
            <td align="char">0.33 ± 0.01</td>
          </tr>
          <tr>
            <td>Signal/Background ratio (&gt;1.2)<xref rid="tblfn1" ref-type="table-fn">a</xref></td>
            <td align="char">1.39 ± 0.04</td>
            <td align="char">1.30 ± 0.03</td>
          </tr>
          <tr>
            <td><italic>Z</italic>′ (&gt;0.5)<xref rid="tblfn2" ref-type="table-fn">b</xref></td>
            <td align="char">0.77 ± 0.08</td>
            <td align="char">0.67 ± 0.08</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p><italic>Note.</italic> Shown are assay performance statistics of <italic>Tb</italic>PTR1 and <italic>Tb</italic>DHFR-TS in the cyt <italic>c</italic>-coupled assay. The assay was carried out in 96-well plates using sodium citrate/EDTA buffer at pH 6.0 and pH 7.4 for <italic>Tb</italic>PTR1 and <italic>Tb</italic>DHFR-TS, respectively. Data shown are means ± standard deviations from 26 plates of assay development and mock screening plates. Values in parentheses represent thresholds of acceptance for screening plate approval.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn1">
          <label>a</label>
          <p>When the signal/background ratio is calculated using reaction rates in the presence and absence of enzyme, a typical ratio for the assay is 43.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn2">
          <label>b</label>
          <p>Eq. <xref rid="fd5" ref-type="disp-formula">(5)</xref><xref rid="bib36" ref-type="bibr">[36]</xref>.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-wrap>
</article>